Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 8:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Anthrax
Interventions
AVP-21D9, Placebo
Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Healthy Participants
Interventions
Mavacamten, Activated Charcoal with Sorbitol
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 60 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Dallas, Texas
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Ciprofloxacin BioThrax Co-Administration Study

NCT01753115
Conditions
Anthrax
Interventions
BioThrax, Ciprofloxacin
Biological · Drug
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Kansas City, Missouri • Omaha, Nebraska • Dallas, Texas
Completed Phase 1 Interventional Accepts healthy volunteers

NasoShield in Healthy Adults to Study Safety and Immunogenicity

NCT04415749
Conditions
Healthy Volunteers
Interventions
NasoShield, Placebo
Biological · Other
Lead sponsor
Altimmune, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Salt Lake City, Utah
Completed Phase 1 Interventional Accepts healthy volunteers

Monoclonal Antibody for Treatment of Inhalation Anthrax

NCT00138411
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Ciprofloxacin 500 mg, ETI-204 (Anthim)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
1
States / cities
Columbus, Ohio
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Velocity 2: An Anthrax Vaccine and Antibiotics Clinical Study

NCT04067011
Conditions
Anthrax
Interventions
Ciprofloxacin 500Mg Tablet, Doxycycline 100Mg Tablet, AV7909
Drug · Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 45 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
4
States / cities
DeLand, Florida • Kansas City, Missouri • Omaha, Nebraska + 1 more
Conditions
Brain Edema, Brain Tumor
Interventions
XERECEPT
Drug
Lead sponsor
Celtic Pharma Development Services
Industry
Eligibility
1 Year to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Boston, Massachusetts
Terminated Phase 1 Interventional Accepts healthy volunteers

Ph1 Study of Valortim and Doxycycline in Humans

NCT00964834
Conditions
Anthrax
Interventions
Doxycycline and Valortim, Placebo Antibiotic and Valortim, Placebo Antibiotic and Placebo Valortim
Drug
Lead sponsor
PharmAthene, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Anthrax
Interventions
Recombinant Protective Antigen, Anthrax Vaccine Adsorbed
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
80 participants
Timeline
2003 – 2005
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

NCT00845650
Conditions
Anthrax
Interventions
AIGIV 3.5 mg/kg, Gamunex 90 mg/kg, AIGIV 7.0 mg/kg, Gamunex 180 mg/kg, AIGIV 14.0 mg/kg, Gamunex 360 mg/kg
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Completed Phase 3 Interventional Accepts healthy volunteers Results available

VELOCITY: An Anthrax Vaccine Clinical Study

NCT03877926
Conditions
Anthrax
Interventions
AV7909, BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
3,689 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
35
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 31 more
Conditions
Inhalational Anthrax
Interventions
ETI-204, Ciprofloxacin
Biological · Drug
Lead sponsor
Elusys Therapeutics
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Overland Park, Kansas
Conditions
Anthrax
Interventions
BioThrax
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
4
States / cities
Miami, Florida • Rochester, New York • Mt. Pleasant, South Carolina + 1 more
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Anthrax Vaccine Clinical Trial to Assess Dose Reduction and Route Change

NCT00119067
Conditions
Healthy
Interventions
Anthrax Vaccine Adsorbed, Saline injection
Biological
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years to 61 Years
Enrollment
1,564 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2010
U.S. locations
5
States / cities
Birmingham, Alabama • Atlanta, Georgia • Silver Spring, Maryland + 2 more
Completed Phase 1Phase 2 Interventional Results available

Glyburide Advantage in Malignant Edema and Stroke Pilot

NCT01268683
Conditions
Ischemic Stroke
Interventions
Glyburide for Injection
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Terminated Phase 2 Interventional Accepts healthy volunteers

UMD rPA Regimen Trial in Adults

NCT00133484
Conditions
Bacillus Anthracis (Anthrax)
Interventions
Anthrax vaccine absorbed made from Bacillus anthracis (AVA), Recombinant protein antigen (rPA) made from Bacillus anthrax, Recombinant protein antigen (rPA) made from Escherichia coli
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 50 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Ends 2007
U.S. locations
2
States / cities
Baltimore, Maryland • Durham, North Carolina
Conditions
Anthrax
Interventions
BW-1010: 50 µg - sprayer - IN, BW-1010: 50 µg - pipette - IN, BW-1010: 100 µg - sprayer - IN, BW-1010: 100 µg - pipette - IN, Saline (Placebo) - sprayer - IN, Saline (Placebo) - pipette - IN, BioThrax (positive control) - SC
Biological
Lead sponsor
BlueWillow Biologics
Industry
Eligibility
18 Years to 49 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Anthrax Infection
Interventions
AVA, Ad4-PA-1, Ad4-PA-GPI-1
Biological
Lead sponsor
Emergent BioSolutions
Industry
Eligibility
18 Years to 40 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
4
States / cities
Kansas City, Kansas • Silver Spring, Maryland • St Louis, Missouri + 1 more
Conditions
Osmolality Disturbance, Lab Interference
Interventions
Activated Charcoal
Drug
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Syracuse, New York
Conditions
Prevention of Anthrax Infection
Interventions
rPA102 Vaccine
Biological
Lead sponsor
VaxGen
Industry
Eligibility
18 Years to 40 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2003
U.S. locations
4
States / cities
Atlanta, Georgia • Baltimore, Maryland • St Louis, Missouri + 1 more
Conditions
HIV Infections
Interventions
HIV LFn-p24
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Rockville, Maryland
Conditions
Anthrax
Interventions
Active Anthrax Detect™ Plus (AAD Plus)
Diagnostic Test
Lead sponsor
InBios International, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Tempe, Arizona • Cincinnati, Ohio • Columbus, Ohio + 1 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Assessment of the Immunogenicity and Safety of a Dose-Sparing BioThrax® AVA Schedule

NCT01641991
Conditions
Bacillus Anthracis (Anthrax)
Interventions
BioThrax®
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Cincinnati, Ohio • Houston, Texas + 1 more